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Sentinel lymph node biopsy in breast cancer patients  
treated with induction chemotherapy should be performed  
after the completion of chemotherapy
Renata Duchnowska
Sentinel lymph node biopsy in patients with early breast cancer treated with breast conserving therapy is currently 
a standard treatment. SLN biopsy allows to resign from the resection of the axillary lymph nodes and thus, to reduce 
the risk of complications and to improve the quality of life of the patients. The objective of preoperative chemotherapy 
is to decrease the scope of surgery both within the primary focus of the tumour and in the axillary lymph nodes. 
The results of the research carried out so far indicate that SLN biopsy, after a preoperative chemotherapy in patients 
at the N0 and N1–2 clinical stage is credible and in allows many of them to avoid the resection of axillary lymph nodes. 
Therefore there are rational arguments justifying SLN biopsy after the completion of preoperative chemotherapy.
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Introduction 
The sentinel lymph node (SLN) is the first lymph node in 
the lymphatic drainage of the primary focus of the tumour. 
It is believed that the SLN is the first site of accumulation of 
tumour cells at the stage of the occurrence of metastases in 
the regional lymph nodes [1–3]. The most frequent method of 
sentinel lymph node identification is preoperative lymphoscin-
tigraphy with the 99mTc radionuclide on an aluminium carrier 
connected with a perioperative staining of lymph drainage 
with methylene blue. In some centres, in order to increase the 
sensitivity of SLN identification, hybrid techniques are used 
i.e. the connection of functional imaging with morphological 
one (SPECT/CT, single photon emission with a low-dose CT) [4]. 
During surgery, the lymph nodes with the largest radioactivity 
and the most stained, which are regarded as SLN are removed. 
It is admitted that the sensitivity of the SLN biopsy should be 
above 90% with the rate of false positive results below 10%. 
The improvement of the rate of identified SLN is significantly 
affected by the number of procedures performed by the sur-
geon, i.e. their experience and practice [5–7].
Preoperative (induction) chemotherapy in breast cancer 
patients is used in order to decrease the advancement stage 
of the primary tumour and/or lymph nodes, which allows 
for a breast conserving procedure. In more advanced cases 
(T4, N2–3 stage), preoperative chemotherapy may facilitate 
or make possible a radical surgery procedure [8]. Currently, 
in patients with so-called aggressive phenotypes, which 
at the same time are characterised with high sensitivity 
to chemotherapy and/or molecularly targeted treatment 
(triple negative cancer and HER2-positive), the induction 
treatment is also often applied in patients in the N0 stage 
if the tumour’s diameter is larger than 2 cm [8, 9]. In the-
se phenotypes, the rate of pathologic complete response 
(pCR,) affects the improvement of survival parameters [9].
Radiotherapy vs axillary lymphadenectomy in 
patients in the N0 clinical stage and a metastasis 
in a sentinel lymph node 
In 3 prospective clinical trials (ACOSOG Z0011, AMAROS, 
IBCSG 23-01) it was shown that in patients with metastases 
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in the SLN, the resection of axillary lymph nodes can be 
avoided. The ACOSOG Z0011 study compared the treatment 
with and without axillary lymphadenectomy in patients 
treated with the BCT and post-operative radiotherapy with 
tangential fields; this led to the conclusion that in the case 
of metastatic involvement of 1 or 2 SLN, the rate of loco-re-
gional recurrences, the time to progression and the overall 
survival periods, are similar after 5 years, in spite of the fact 
that in the group undergoing axillary lymphadenectomy in 
about 30% patients, the metastases to consecutive lymph 
nodes were found [10]. The AMAROS study showed that 
axillary irradiation is equally effective as surgery with a much 
lower risk of complications [11]. Similar results were rende-
red by the IBCSG 23-01 study which concerned patients with 
micro-metastases in SLN [12]. 
Preoperative chemotherapy  
in patients at the N0 clinical stage 
Before the commencement of preoperative chemothe-
rapy in patients at the cN0 stage, a number of additional 
tests must be performed, including an ultrasound of the 
axilla, connected, when metastases are suspected, with 
a biopsy of axillary lymph nodes and also to mark the prima-
ry tumour with clips or a tattoo. In some centres, in order to 
evaluate the advancement stage, additionally a breast MRI 
or position computed tomography (PET/CT) is performed. 
Postponing the SLN biopsy until the moment of completion 
of preoperative chemotherapy does not significantly reduce 
the accuracy of the examination; the rate of identified SLN 
in this group is more than 90%, and false negative results 
concern 6–9% of patients [13–15]. That is why, international 
guidelines, including those from the most recent conferen-
ces on the treatment of early breast cancer — St. Gallen, 
recommend the SLN biopsy in patients at the N0 stage after 
the completion of preoperative chemotherapy [8, www.
oncoconferences.ch/BCC]. 
Preoperative chemotherapy in the patients  
at the N+ clinical stage 
In the case of diagnosing clinical cN+ stage and its con-
formation with a fine needle biopsy, there is no need to 
perform an SLN biopsy before preoperative chemotherapy, 
as this procedure is performed solely in patients without 
pathological or clinical symptoms of metastatic involvement 
of axillary lymph nodes. Regardless of the above, SLN biopsy 
before preoperative chemotherapy would not change the 
clinical stage and thus would not affect the choice of the 
type of surgical intervention, but it would increase the risk 
of complications and diagnostic costs. It must be remembe-
red that the main objective of preoperative chemotherapy, 
apart for guaranteeing the possibility of BCT, is to avoid 
axillary lymphadenectomy. A few studies have shown that 
the pCR rate within the lymph nodes after preoperative che-
motherapy, especially in the following phenotypes: triple-
-negative and HER2-positive, amounts to 40–50% [16–18] 
(Tab. I). What is important, axillary lymphadenectomy may 
be avoided in about 50% of patients with SLN biopsy, con-
firmed with pCR, after pre-operative chemotherapy espe-
cially that the majority of them, an account of the base-
line metastatic involvement of the axillary lymph nodes, 
will undergo radiotherapy of the nodal fields [8, 16–18] 
(www.oncoconferences.ch/BCC). This fits to the generally 
accepted tendency to limit axillary lymphadenectomies 
in breast cancer patients [www.oncoconferences.ch/BCC]. 
What is more, in spite of earlier concerns about SLN identifi-
cation after preoperative chemotherapy and the high risk of 
false negative results, a prospective analysis of the ACOSOG 
Z1071 and SENTINA studies, has shown that the sensitivity of 
the SLN biopsy in the case of the removal of at least 3 SLNs 
is larger than 90%, and the rate of false negative results fits 
in the range of 10% [19, 20]. 
Summary
Preoperative chemotherapy is used mostly with the 
intention of reducing the scope of a surgery, also in relation 
to the axillary lymph nodes The results of the studies carried 
out so far show that SLN biopsy after preoperative chemo-
therapy is a reliable method, allowing, in a large group of pa-
tients, to avoid axillary lymphadenectomy. Such a possibility 
is not guaranteed by SLN biopsy before the commencement 
of preoperative chemotherapy. As a consequence, currently 
the SLN biopsy after the completion of chemotherapy is 
becoming a standard treatment method, irrespective of the 
baseline status of the axillary lymph nodes [8, 19–21, www.
oncoconferences.ch/BCC].
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Table I. pCR rate within the lymph nodes after preoperative chemotherapy
Study N The rate of pCR in the 
lymph nodes 
ACOSOG Z1071 (cT0–4N1/2)16 649 41%
SN FNAC (cT0–3N1/2)17 145 35%
Mamtani (cT0–3N1/2)18 195 49%
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